Overview

Enstilar in Combination With Biologic Agents

Status:
Completed
Trial end date:
2017-10-30
Target enrollment:
Participant gender:
Summary
Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Collaborator:
LEO Pharma
Treatments:
Betamethasone
Betamethasone-17,21-dipropionate
Calcipotriene
Calcitriol